The company showcased its TMB-365-ADC, the world's first antibody-drug conjugate designed specifically for HIV treatment, demonstrating precise CD4⁺ immune cell targeting and potent antiviral activity. This innovation represents a new strategic approach for precision HIV therapy, functional cure, and long-term disease management.
The core design of TMB-365-ADC originates from TaiMed's commercialized drug Trogarzo® (ibalizumab), through an advanced engineering of its long-acting variant TMB-365. TMB-365 is a broad and durable antibody that blocks HIV-1 entry into CD4⁺ immune cells. By linking it to an integrase inhibitor payload (INSTI) via ADC technology, the conjugate maintains dual function antiviral activity and enhances resistance barrier, while significantly reducing systemic toxicity.
In its preclinical studies, TMB-365-ADC achieved four major proof-of-concept milestones:
• High Target Specificity: Capable of selectively binding and internalizing into CD4⁺ immune cells - the primary viral reservoir - achieving precise drug delivery.
Contact CDMO Service